The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant improvements in psychotic symptoms and cognition with a favorable safety profile. The BID dose demonstrated robust efficacy and tolerability, supporting advancement to pivotal studies and potentia…
The phase II ZEPHYR study of ML-007C-MA in schizophrenia met its primary endpoint, showing significant improvements in psychotic symptoms and cognition with a favorable safety profile. The BID dose demonstrated robust efficacy and tolerability, supporting advancement to pivotal studies and potential use in Alzheimer's disease psychosis.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
